Evidence map›Paper›PMID 38643358›Full record

SynthesisMedical science monitor : international medical journal of experimental and clinical research2024

Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, and High-Income Countries: A Systematic Review.

Abdul Khairul Rizki Purba, Alfian Nur Rosyid, Samsriyaningsih Handayani, Brian Eka Rachman, Achmad Chusnu Romdhoni, Makhyan Jibril Al Farabi, Joni Wahyuhadi, Rosita Prananingtias, Ainun Nitsa Rahayu, Firas Farisi Alkaff and 5 more

Abstract readSystematic Review
In one paragraph

Synthesis in Medical science monitor : international medical journal of experimental and clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Abdul Khairul Rizki PurbaDivision of Pharmacology and Therapy, Department of Anatomy Histology and Pharmacology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.ORCID 0000-0002-9372-2656
Alfian Nur RosyidDepartment of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.
Samsriyaningsih HandayaniDepartment of Public Health and Preventive Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.
Brian Eka RachmanDepartment of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.ORCID 0000-0002-9113-1297
Achmad Chusnu RomdhoniDepartment of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.
Makhyan Jibril Al FarabiDepartment of Cardiology and Vascular Medicine, Universitas Airlangga/Soetomo General Hospital, Surabaya, East Java, Indonesia.
Joni WahyuhadiDepartment of Neurosurgery, Faculty of medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.
Rosita PrananingtiasDepartment of Medical Record, Universitas Airlangga Hospital, Surabaya, East Java, Indonesia.
Ainun Nitsa RahayuFaculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.
Firas Farisi AlkaffDivision of Pharmacology and Therapy, Department of Anatomy, Histology, and Pharmacology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.ORCID 0000-0002-5628-1345
Yufi Aulia AzmiDepartment of Urology, Faculty of Medicine, Universitas Airlangga-Dr. Soetomo General Academic Hospital, Surabaya, East Java, Indonesia.ORCID 0000-0002-9947-2432
Sabarinah PrasetyoDepartment of Biostatistic and Population Studies, Faculty of Public Health, Universitas Indonesia, Depok, West Java, Indonesia.
Mardiati NadjibDepartment of Health Administration and Health Policy, Faculty of Public Health, Universitas Indonesia, Depok, West Java, Indonesia.
Lina Patricia GutjahrFaculty of Medicine, Saarland University, Saarbrücken, Germany.
Raudia Faridah HumaidyDepartment of Public Health and Preventive Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Economic evaluation of the testing strategies to control transmission and monitor the severity of COVID-19 after the pandemic is essential. This study aimed to review the economic evaluation of COVID-19 tests and to construct a model with outcomes in terms of cost and test acceptability for surveillance in the post-pandemic period in low-income, middle-income, and high-income countries. MATERIAL AND METHODS We performed the systematic review following PRISMA guidelines through MEDLINE and EMBASE databases. We included the relevant studies that reported the economic evaluation of COVID-19 tests for surveillance. Also, we input current probability, sensitivity, and specificity for COVID-19 surveillance in the post-pandemic period. RESULTS A total of 104 articles met the eligibility criteria, and 8 articles were reviewed and assessed for quality. The specificity and sensitivity of COVID-19 screening tests were reported as 80% to 90% and 40% to 90%, respectively. The target population presented a mortality rate between 0.2% and 19.2% in the post-pandemic period. The implementation model of COVID-19 screening tests for surveillance with a cost mean for molecular and antigen tests was US$ 46.64 (min-max US $0.25-$105.39) and US $6.15 (min-max US $2-$10), respectively. CONCLUSIONS For the allocation budget for the COVID-19 surveillance test, it is essential to consider the incidence and mortality of the post-pandemic period in low-income, middle-income, and high-income countries. A robust method to evaluate outcomes is needed to prevent increasing COVID-19 incidents earlier.

Indexed as

COVID-19COVID-19 TestingDeveloping CountriesMass ScreeningCost-Benefit AnalysisDeveloped CountriesHumansIncomePandemicsSARS-CoV-2Sensitivity and Specificity

Identifiers

PMID38643358
PMCPMC11044836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.